Study Condition(s): Stomach Cancer, Gastroesophageal Junction Cancer (GEJ), Advanced Cancer

A Study of LY2801653 in Participants With Advanced Cancer

Study Alias: JSBA

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT01285037 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to determine a recommended phase 2 dose of LY2801653 that may be safely given to participants with gastric cancer when taken with ramucirumab.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18+ years

Time Commitment

Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
  • Participant must have stomach cancer, including stomach adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma (participants with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the GEJ) confirmed by histology or cytology
  • Participant must provide a mandatory tumor tissue sample, when safe and feasible, for biomarker analysis
  • Participant must be able to swallow capsules or have the study drug crushed and administered through a feeding tube
  • Female participants must not be pregnant or breastfeeding
  • Participants must not have liver cancer, liver cirrhosis with a Child-Pugh stage of B or higher, or received a liver transplant

Where to Participate

7 locations are currently available of 7 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.